8-K
filed June 20, 2023, 7:59 PM ET
ticker CCCC
CIK 0001662579
leadership
confidence high
sentiment positive
materiality 0.60
C4 Therapeutics appoints Leonard Reyno, M.D. as Chief Medical Officer effective July 10, 2023
C4 Therapeutics, Inc.
- Dr. Reyno receives $550K base salary, $200K sign-on bonus, and up to 40% performance bonus.
- Inducement option for 276,000 shares (25% vests year 1, rest quarterly over three years) plus 61,300 RSUs vesting over four years.
- Reyno brings ~30 years of oncology clinical experience; previously led Padcev early development, Herceptin and Taxotere FDA approvals.
- Stockholders elected three Class III directors, approved executive compensation, ratified KPMG as auditor, and approved officer liability limitation charter amendment.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Leonard M.J. Reyno, M.D. was appointed as Chief Medical Officer at C4 Therapeutics, Inc..
- Action
- appointed
- Role
- Chief Medical Officer
Exact text from the filing
On June 20, 2023, C4 Therapeutics, Inc. (the “ Company ” or “ us ”), announced the appointment of Leonard M.J. Reyno, M.D. as its Chief Medical Officer, effective as of July 10, 2023.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
C4 Therapeutics, Inc. shareholders approved Non-binding advisory vote to approve compensation of named executive officers at the 2023-06-15 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-06-15
Exact text from the filing
The stockholders of the Company cast a non-binding, advisory vote to approve the compensation of the Company’s named executive officers.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
C4 Therapeutics, Inc. shareholders approved Amendment to Fifth Amended and Restated Certificate of Incorporation to limit liability of certain officers as permitted by Delaware law at the 2023-06-15 meeting.
- Proposal
- charter amendment
- Outcome
- passed
- Meeting
- 2023-06-15
Exact text from the filing
The stockholders of the Company approved the amendment to the Company’s Fifth Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company as permitted by recent amendments to Delaware law.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
C4 Therapeutics, Inc. shareholders approved Election of Class III directors at the 2023-06-15 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-15
Exact text from the filing
The stockholders of the Company elected each of Andrew J. Hirsch, Utpal Koppikar and Malcom Salter as Class III directors, to hold office until the 2026 annual meeting of stockholders and until their respective successors have been duly elected and qualified or until his or her earlier resignation or removal.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
C4 Therapeutics, Inc. shareholders approved Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-15 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-15
Exact text from the filing
The stockholders of the Company ratified the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.